Myriad Genetics Inc (MYGN)vsWaters Corporation (WAT)
MYGN
Myriad Genetics Inc
$4.69
+6.59%
HEALTHCARE · Cap: $414.63M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 577% more annual revenue ($3.77B vs $557.00M). WAT leads profitability with a 11.9% profit margin vs -41.3%. MYGN appears more attractively valued with a PEG of 1.24. WAT earns a higher WallStSmart Score of 50/100 (C-).
MYGN
Hold44
out of 100
Grade: D
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.7%
Fair Value
$46.95
Current Price
$4.69
$42.26 discount
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 20.8%
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.24 suggests the stock is reasonably priced for its growth.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
MYGN profiles as a turnaround stock while WAT is a growth play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
MYGN generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 44/100) and 91.4% revenue growth. MYGN offers better value entry with a 89.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?